NASDAQ:SNSE Sensei Biotherapeutics (SNSE) Stock Price, News & Analysis $16.60 +0.75 (+4.73%) Closing price 04:00 PM EasternExtended Trading$16.60 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sensei Biotherapeutics Stock (NASDAQ:SNSE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sensei Biotherapeutics alerts:Sign Up Key Stats Today's Range$15.23▼$17.9050-Day Range$15.85▼$34.7952-Week Range$5.60▼$36.76Volume36,794 shsAverage Volume201,060 shsMarket Capitalization$22.24 millionP/E RatioN/ADividend YieldN/APrice Target$46.25Consensus RatingHold Company Overview Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies. The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways. In addition to these clinical-stage candidates, Sensei is advancing preclinical projects against novel innate immune checkpoints and exploring combination regimens to broaden therapeutic impact. Founded in 2018 and headquartered in Cambridge, Massachusetts, Sensei Biotherapeutics operates across the United States and collaborates with academic and industry partners to accelerate research and development. The company’s leadership team brings extensive experience in antibody therapeutics, translational research and clinical development, supporting its mission to bring innovative immunotherapies through clinical trials and deliver new treatment options for patients worldwide.AI Generated. May Contain Errors. Read More Sensei Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreSNSE MarketRank™: Sensei Biotherapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 457th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingSensei Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialSensei Biotherapeutics has a consensus price target of $46.25, representing about 184.3% upside from its current price of $16.27.Amount of Analyst CoverageSensei Biotherapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sensei Biotherapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Sensei Biotherapeutics are expected to decrease in the coming year, from ($2.77) to ($3.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sensei Biotherapeutics is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sensei Biotherapeutics is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSensei Biotherapeutics has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sensei Biotherapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted79.10% of the float of Sensei Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverSensei Biotherapeutics has a short interest ratio ("days to cover") of 28.35, which indicates bearish sentiment.Change versus previous monthShort interest in Sensei Biotherapeutics has recently decreased by 2.26%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSensei Biotherapeutics does not currently pay a dividend.Dividend GrowthSensei Biotherapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.28 News SentimentSensei Biotherapeutics has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Sensei Biotherapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for SNSE on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days. Company Ownership3.2 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $136,730.00 in company stock, which represents 0.6272% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Sensei Biotherapeutics insiders have bought 11.35% more of their company's stock than they have sold. Specifically, they have bought $1,341,669.00 in company stock and sold $1,204,939.00 in company stock.Percentage Held by Insiders7.00% of the stock of Sensei Biotherapeutics is held by insiders.Percentage Held by Institutions10.50% of the stock of Sensei Biotherapeutics is held by institutions.Read more about Sensei Biotherapeutics' insider trading history. Receive SNSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sensei Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNSE Stock News HeadlinesMost and least shorted healthcare stocks with market cap up to $2B at the end of MayJune 3 at 1:47 PM | seekingalpha.comSensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder James Peyer Sells 25,000 Shares of StockJune 3 at 4:04 AM | americanbankingnews.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.June 4 at 1:00 AM | Porter & Company (Ad)Insider Selling: Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Sells 25,000 Shares of StockJune 2 at 4:33 AM | insidertrades.comCantor Fitzgerald initiates coverage of Sensei Biotherapeutics (SNSE) with overweight recommendationMay 30, 2026 | msn.comCitigroup initiates coverage of Sensei Biotherapeutics (SNSE) with buy recommendationMay 24, 2026 | msn.comSensei Biotherapeutics Updates 2026 Board Reconstitution PlansMay 22, 2026 | tipranks.comSensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Purchases $164,021.22 in StockMay 16, 2026 | insidertrades.comSee More Headlines SNSE Stock Analysis - Frequently Asked Questions How have SNSE shares performed this year? Sensei Biotherapeutics' stock was trading at $10.67 at the beginning of the year. Since then, SNSE shares have increased by 52.5% and is now trading at $16.27. How were Sensei Biotherapeutics' earnings last quarter? Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) issued its earnings results on Friday, May, 15th. The company reported ($131.45) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by $130.83. When did Sensei Biotherapeutics' stock split? Shares of Sensei Biotherapeutics reverse split on Tuesday, June 17th 2025.The 1-20 reverse split was announced on Friday, June 13th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 16th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Sensei Biotherapeutics IPO? Sensei Biotherapeutics (SNSE) raised $100 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 5,900,000 shares at $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. served as the underwriters for the IPO. Who are Sensei Biotherapeutics' major shareholders? Top institutional shareholders of Sensei Biotherapeutics include Vivo Capital LLC (53.88%), Stempoint Capital LP (9.92%), Bank of America Corp DE (2.46%) and Renaissance Technologies LLC (2.39%). Insiders that own company stock include Millennium Management Llc, James Peyer and John Celebi. View institutional ownership trends. How do I buy shares of Sensei Biotherapeutics? Shares of SNSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sensei Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sensei Biotherapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Tesla (TSLA), Advanced Micro Devices (AMD), Plug Power (PLUG), PayPal (PYPL) and Walt Disney (DIS). Company Calendar Last Earnings5/15/2026Today6/04/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3d) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 As of 3 days ago, SNSE's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SNSE CIK1829802 Webwww.senseibio.com Phone240-243-8000FaxN/AEmployees40Year Founded1999Price Target and Rating Average Price Target for Sensei Biotherapeutics$46.25 High Price Target$55.00 Low Price Target$30.00 Potential Upside/Downside+184.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($142.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.08 million Net MarginsN/A Pretax MarginN/A Return on Equity-83.59% Return on Assets-256.50% Debt Debt-to-Equity RatioN/A Current Ratio14.39 Quick Ratio14.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.74 per share Price / Book1.10Miscellaneous Outstanding Shares1,340,000Free Float1,248,000Market Cap$21.80 million OptionableNot Optionable Beta-0.25 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:SNSE) was last updated on 6/4/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | SponsoredGiving “2022 pre-ChatGPT” vibes (but 10x bigger)When ChatGPT launched in 2022, Nvidia surged 1,800% over three years. Now, Nvidia's CEO suggests July 22nd cou...StocksToTrade | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredWhere did Vanguard quietly put $101 billion?Tech investor George Gilder spent 40 years identifying paradigm shifts before they went mainstream - flagging ...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sensei Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
